Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Pediatric Oncology
•
Medical Oncology
•
Bone Marrow Transplant
•
AYA
•
Cancer Predisposition
•
Hematology
Would you have toxicity concerns for offering a myeloablative conditioning regimen to an AYA patient with acute lymphoblastic leukemia and a germline BRCA2 mutation?
If so, what conditioning regimens might you consider as an alternative?
Related Questions
Would you use a matched sibling donor with a germline heterozygous BRCA1 mutation for stem cell transplant?
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?
How do you approach autologous stem cell transplant in T-cell lymphomas/PTCL after induction chemotherapy with achievement of CR1?
What are your top takeaways from ASH 2023?
What is your approach to treating a young adult with severe aplastic anemia unresponsive to steroids and TPO-mimetics?
Would you consider post-BMT maintenance therapy for patients with Ph-like ALL with a JAK2 mutation?
What is the preferred approach for an AYA patient with VHR B-ALL with iAMP21 mutation with an isolated early CNS relapse?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
What is your approach to cancer patients who inquire about alternative or complementary treatments?